Last reviewed · How we verify
Dexamethasone 0.1% and tobramycin 0.3% — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexamethasone 0.1% and tobramycin 0.3% (Dexamethasone 0.1% and tobramycin 0.3%) — Bausch & Lomb Incorporated.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexamethasone 0.1% and tobramycin 0.3% TARGET | Dexamethasone 0.1% and tobramycin 0.3% | Bausch & Lomb Incorporated | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexamethasone 0.1% and tobramycin 0.3% CI watch — RSS
- Dexamethasone 0.1% and tobramycin 0.3% CI watch — Atom
- Dexamethasone 0.1% and tobramycin 0.3% CI watch — JSON
- Dexamethasone 0.1% and tobramycin 0.3% alone — RSS
Cite this brief
Drug Landscape (2026). Dexamethasone 0.1% and tobramycin 0.3% — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-0-1-and-tobramycin-0-3. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab